title: Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study. Effects of Polygonum Cuspidatum Containing Resveratrol on Inflammation in Male Professional Basketball Players Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial. Quercetin and Vitamin C Supplementation: Effects on Lipid Profile and Muscle Damage in Male Athletes Effects of Cinnamon, Cardamom, Saffron, and Ginger Consumption on Markers of Glycemic Control, Lipid Profile, Oxidative Stress, and Inflammation in Type 2 Diabetes Patients. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Alterations of antioxidant status in asymptomatic hypercholesterolemic individuals after resveratrol intake Effect of Probiotic Soy Milk on Serum Levels of Adiponectin, Inflammatory Mediators, Lipid Profile, and Fasting Blood Glucose Among Patients with Type II Diabetes Mellitus The Impact of Resveratrol Supplementation on Blood Glucose, Insulin, Insulin Resistance, Triglyceride, and Periodontal Markers in Type 2 Diabetic Patients with Chronic Periodontitis Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: A randomized trial. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Effects of chronic resveratrol supplementation in military firefighters undergo a physical fitness test--a placebo-controlled, double blind study.
abstract: ABSTRACT Objective “ The obesity epidemic ” has led to an increase in obesity-related conditions including non-alcoholic fatty liver disease ( NAFLD ) , for which effective treatments are in dem and . The polyphenol resveratrol prevents the development of experimental NAFLD through modulation of cellular pathways involved in calorie restriction . We aim ed to test the hypothesis that resveratrol alleviates NAFLD in a r and omised , clinical trial . Material s and methods A total of 28 overweight patients with transaminasemia and histological NAFLD were r and omised 1:1 to placebo or resveratrol 1.5 g daily for 6 months . Twenty-six participants completed the trial and underwent repeated clinical investigation , blood work , MR spectroscopy ; and 19 participants agreed to a repeat liver biopsy . Results Resveratrol treatment was generally not superior to placebo in improving plasma markers of liver injury ( primary outcome : alanine transaminase , p = 0.51 ) . Resveratrol-treated patients showed a 3.8 % decrease in liver lipid content ( p = 0.03 ) , with no difference between the two treatment arms ( p = 0.38 ) and no improvement of histological features .  Resveratrol treatment was not associated with improvements in insulin sensitivity or markers of the metabolic syndrome , except for a transient decrease in systolic BP . Microarray analysis and qRT-PCR revealed no major changes in expression profile . Also , we report a serious adverse event in a patient who developed fever and bicytopenia . Conclusions In this placebo-controlled , high-dose and long-term study , resveratrol treatment had no consistent therapeutic effect in alleviating clinical or histological NAFLD , though there may be a small ameliorating effect on liver function tests and liver fat accumulation Ageing is thought to be associated with decreased vascular function partly due to oxidative stress . Resveratrol is a polyphenol , which in animal studies has been shown to decrease atherosclerosis , and improve cardiovascular health and physical capacity , in part through its effects on Sirtuin 1 signalling and through an improved antioxidant capacity . We tested the hypothesis that resveratrol supplementation enhances training-induced improvements in cardiovascular health parameters in aged men . Twenty-seven healthy physically inactive aged men ( age : 65 ± 1 years ; body mass index : 25.4 ± 0.7 kg m(-2 ) ; mean arterial pressure ( MAP ) : 95.8 ± 2.2 mmHg ; maximal oxygen uptake : 2488 ± 72 ml O2 min(-1 ) ) were r and omized into 8 weeks of either daily intake of either 250 mg trans-resveratrol ( n = 14 ) or of placebo ( n = 13 ) concomitant with high-intensity exercise training . Exercise training led to a 45 % greater ( P < 0.05 ) increase in maximal oxygen uptake in the placebo group than in the resveratrol group and to a decrease in MAP in the placebo group only ( -4.8 ± 1.7 mmHg ; P < 0.05 ) . The interstitial level of vasodilator prostacyclin was lower in the resveratrol than in the placebo group after training ( 980 ± 90 vs. 1174 ± 121 pg ml(-1 ) ; P < 0.02 ) and muscle thromboxane synthase was higher in the resveratrol group after training ( P < 0.05 ) . Resveratrol administration also abolished the positive effects of exercise on low-density lipoprotein , total cholesterol/high-density lipoprotein ratio and triglyceride concentrations in blood ( P < 0.05 ) . Resveratrol did not alter the effect of exercise training on the atherosclerosis marker vascular cell adhesion molecule 1 ( VCAM-1 ) . Sirtuin 1 protein levels were not affected by resveratrol supplementation . These findings indicate that , whereas exercise training effectively improves several cardiovascular health parameters in aged men , concomitant resveratrol supplementation can blunt these effects Resveratrol is a naturally occurring polyphenolic compound . Numerous animal studies have been reported on its wide-ranging beneficial effects in the biological system including diabetes mellitus ( DM ) . We hypothesized , therefore , that oral supplementation of resveratrol would improve the glycemic control and the associated risk factors in patients with type 2 diabetes mellitus ( T2DM ) . The present clinical study was therefore carried out to test the hypothesis . Sixty-two patients with T2DM were enrolled from Government Headquarters Hospital , Ootacamund , India , in a prospect i ve , open-label , r and omized , controlled trial . Patients were r and omized into control and intervention groups . The control group received only oral hypoglycemic agents , whereas the intervention group received resveratrol ( 250 mg/d ) along with their oral hypoglycemic agents for a period of 3 months . Hemoglobin A(1c ) , lipid profile , urea nitrogen , creatinine , and protein were measured at the baseline and at the end of 3 months . The results reveal that supplementation of resveratrol for 3 months significantly improves the mean hemoglobin A(1c ) ( means ± SD , 9.99 ± 1.50 vs 9.65 ± 1.54 ; P < .05 ) , systolic blood pressure ( mean ± SD , 139.71 ± 16.10 vs 127.92 ± 15.37 ; P < .05 ) , total cholesterol ( mean ± SD , 4.70 ± 0.90 vs 4.33 ± 0.76 ; P < .05 ) , and total protein ( mean ± SD , 75.6 ± 4.6 vs 72.3 ± 6.2 ; P < .05 ) in T2DM . No significant changes in body weight and high-density lipoprotein and low-density lipoprotein cholesterols were observed . Oral supplementation of resveratrol is thus found to be effective in improving glycemic control and may possibly provide a potential adjuvant for the treatment and management of diabetes Background : Patients with schizophrenia ( SZ ) are generally overweight or obese and have several metabolic disorders . Additionally , such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease ( CVD ) . The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ . Methods and Results : This is a four-week r and omized , double-blind controlled trial ( registration No. : NCT 02062190 ) in which 19 men with a diagnosis of SZ , aged 18 to 65 , were assigned to either a resveratrol supplement group ( 200 mg/day ) or a placebo group ( 200 mg/day ) . In short , we did not observe significant changes after resveratrol supplementation . In the placebo group , we found a significant increase in total cholesterol levels ( p = 0.024 ) and in LDL-cholesterol ( p = 0.002 ) , as well as a decrease in body fat percentage ( p = 0.038 ) . The placebo group also showed an increase in triglycerides ( 9.19 % ) and a reduction in HDL-cholesterol ( 4.88 % ) . In the resveratrol group , triglycerides decreased ( 7.64 % ) . Conclusion : In summary , oral resveratrol in reasonably low dosages ( 200 mg daily ) brought no differences to body weight , waist circumference , glucose , and total cholesterol . It was possible to note that the lipid profile in the placebo group worsened and , although no significant differences were found , we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels To assess the effect on exercise capacity and tolerability of resveratrol , 13 healthy , sedentary adult volunteers were enrolled in a r and omized crossover study comparing resveratrol and placebo over two 4-week periods , with a 2-week time between periods when subjects received no treatment . No significant changes in exercise duration or aerobic capacity ( peak oxygen uptake ) were observed . Gastrointestinal side effects were more common during resveratrol treatment ( 77 % vs. 15 % , p = 0.0048 ) . A small reduction in fasting glucose and small but statistically significant increases in liver enzymes , total cholesterol , and triglycerides were observed , although mean results remained within normal limits . There was no change in complete blood count , inflammatory markers , renal function , or other measures of liver function Background : Exercise can lead to acute oxidative stress , which can result in oxidative damage and induce inflammation . Resveratrol may reduce the levels of inflammatory cytokines . Thus , we investigated the effects of this compound on the plasma levels of tumor necrosis factor-α ( TNF-α ) and interleukin 6 ( IL-6 ) in male professional basketball players . Methods : Twenty healthy male professional basketball players were r and omized into two groups ( 10 each ) . For 6 weeks , they received daily either 200 mg of polygonum cuspidatum extract ( PCE ) st and ardized to contain 20 % trans-resveratrol equivalent to 40 mg trans-resveratrol or placebo . Indices of inflammation were measured before and after 6 weeks of supplementation . Results : There was a significant reduction in plasma levels of TNF-a and IL-6 after 6 weeks of supplementation ; while no change was observed in these markers in the control group . Conclusions : Present study shows that 6 weeks of PCE containing resveratrol supplementation reduces the inflammation in male professional basketball players The polyphenol resveratrol is considered to exert many beneficial actions , such as antioxidant , anti-inflammatory , insulin-sensitizer and anticancer effects . Its benefits in patients with type 2 diabetes mellitus ( T2DM ) are controversial . Our aims were to determine whether resveratrol supplementation at two different dosages ( 500 and 40mg/day ) for 6 months i ) reduced the concentrations of C-reactive-protein ( CRP ) and ii ) ameliorated the metabolic pattern of T2DM patients .  In the present double-blind , r and omized , placebo-controlled trial , 192 T2DM patients were r and omized to receive resveratrol 500mg/day ( Resv500arm ) , resveratrol 40mg/day ( Resv40arm ) or placebo for 6-months . At baseline and at the trial end , CRP values , anthropometric , metabolic and liver parameters were determined . No serious adverse event occurred . A dose-dependent , though not significant , CRP decrease of 5.6 % ( Resv40arm ) and 15.9 % ( Resv500arm ) was observed vs placebo . We failed to detect significant differences in weight , BMI , waist circumference , and values of arterial blood pressure , fasting glucose , glycated hemoglobin , insulin , C-peptide , free fatty acids , liver transaminases , uric acid , adiponectin , interleukin-6 , in both the Resv500 and Resv40 arms vs placebo . Total cholesterol and triglycerides slightly increased in the Resv500arm . Subgroup analyses revealed that lower diabetes duration ( in both Resv500 and Resv40arms ) , and , in the Resv500arm , younger age , aspirin use and being a smoker were associated with a significantly higher CRP reduction vs placebo . The supplementations with 40mg/day or 500mg/day resveratrol did neither reduce CRP concentrations , nor improve the metabolic pattern of T2DM patients CONTEXT Polycystic ovary syndrome ( PCOS ) is the most common endocrinopathy affecting women of reproductive age . Hyper and rogenism is the central feature of PCOS . Studies on isolated ovarian theca-interstitial cells suggest that resveratrol , a natural polyphenol , reduces and rogen production . OBJECTIVE This study was design ed to evaluate endocrine and metabolic effects of resveratrol on PCOS . DESIGN AND SETTING This was a r and omized ( 1:1 ) double-blind , placebo-controlled trial that evaluated the effects of resveratrol over a period of 3 months in an academic hospital . PATIENTS AND OTHER PARTICIPANTS Subjects with PCOS were identified according to the Rotterdam criteria . Thirty-four subjects were enrolled and 30 subjects completed the trial . Evaluations were performed at baseline and repeated after 3 months of treatment . INTERVENTION Resveratrol ( 1,500 mg p.o . ) or placebo were administered daily . MAIN OUTCOME MEASURE Primary outcome was the change in the serum total T. RESULTS Resveratrol treatment led to a significant decrease of total T by 23.1 % ( P = .01 ) . In parallel , resveratrol induced a 22.2 % decrease of dehydroepi and rosterone sulfate ( P = .01 ) , a decrease of fasting insulin level by 31.8 % ( P = .007 ) and an increase of the Insulin Sensitivity Index ( Matsuda and DeFronzo ) by 66.3 % ( P = .04 ) . Levels of gonadotropins , the lipid profile as well as markers of inflammation and endothelial function were not significantly altered . CONCLUSIONS Resveratrol significantly reduced ovarian and adrenal and rogens . This effect may be , at least in part , related to an improvement of insulin sensitivity and a decline of insulin level Background : Quercetin , which is considered as a health-promoting antioxidant , belongs to the broad flavonoids group . Numerous experimental studies have proved that quercetin and vitamin C provide anti-inflammatory and antioxidant properties . The aim of this study is to assess the effects of both quercetin and vitamin C on lipid profile and muscle damage in human subjects . Methods : A r and omized , placebo-controlled , double-blind clinical trial was carried out on 60 males for eight weeks . The subjects were r and omly assigned to one of the four groups : 1 ) quercetin + vitamin C ( 500 mg/day quercetin + 200 mg/day vitamin C ) 2 ) quercetin ( 500 mg/day quercetin + 200 mg/day placebo ) 3 ) vitamin C ( 500 mg/day vitamin C + 200 mg/day placebo ) and 4 ) placebo ( 500 mg/day placebo + 200 mg/day placebo ) . Blood sample s , body weight and percent of body fat were measured before and after intervention . In addition , dietary intake was estimated using 24-h recall . Results : No significant changes occurred in high-density lipoprotein levels between groups and in the four groups before and after supplementation . Low density lipoprotein values decreased significantly ( P = 0.048 ) in the “ Quercetin + Vit C ” group but decrease was not considerable in other groups before and after intervention and among groups . Fat-soluble vitamins ' intake was significantly high among 4 groups . Conclusions : Quercetin and vitamin C supplementation may not be beneficial in lipid profile improvement , although it may reduce induce muscle damage and body fat percent OBJECTIVES Type 2 diabetes ( T2D ) may be caused by elevated oxidative stress , inflammation , and hyperglycemia . The phytochemicals in several herbal medicines are reported to effectively improve diabetes and to ameliorate diabetic complications . The aim of the present study was to determine the effects of cinnamon , cardamom , saffron , and ginger as supplementary remedies in T2D . METHODS This r and omized controlled , clinical trial included 204 T2D patients . The participants were r and omly assigned to four intervention groups receiving 3 glasses of black tea and either 3 g cardamom , or cinnamon , or ginger , or 1 g saffron and one control group which consumed only 3 tea glasses without any herbal medicine for 8 weeks . Markers of inflammation , oxidative stress , fasting blood sugar , lipid profile , and anthropometric measures were evaluated at baseline and after 8 weeks of intervention . RESULTS After 8 weeks of intervention , cinnamon , cardamom , ginger , and saffron consumption had significant effects on total cholesterol , LDL , and HDL levels ( p < 0.05 ) compared with controls . However , the herbal products did not have significant effects on measures of glycemic control , anthropometry , inflammation , and oxidative stress . In within-group comparisons only , cinnamon intake significantly decreased fasting blood sugar ( FBS ) . CONCLUSIONS The herbal remedies examined had significantly beneficial effects on cholesterol , but not on measures of glycemic control , oxidative stress , and inflammation . Based on the contradictory results reported in the literature , the effects of herbal medicine in diabetic patients should undergo further detailed investigation BACKGROUND Despite their powerful biologic activities conducive to protection against atherosclerosis , cancer and inflammatory diseases demonstrated in vitro , there is considerable doubt whether the polyphenolic constituents present in red wine and other dietary components are effective in vivo . OBJECTIVE We have tested the absorptive efficiency of three of these constituents ( trans-resveratrol , [+]-catechin and quercetin ) when given orally to healthy human subjects in three different media . DESIGN Twelve healthy males aged 25 to 45 were r and omly assigned to three different groups consuming orally one of the following polyphenols : trans-resveratrol , 25 mg/70 kg ; [+]-catechin 25 mg/70 kg ; quercetin 10 mg/70 kg . Each polyphenol was r and omly administered at 4-week intervals in three different matrices : white wine ( 11.5 % ethanol ) , grape juice , and vegetable juice/homogenate . Blood was collected at zero time and at four intervals over the first four hours after consumption ; urine was collected at zero time and for the following 24-h . The sums of free and conjugated polyphenols were measured in blood serum and urine by a gas-chromatographic method . RESULTS All three polyphenols were present in serum and urine predominantly as glucuronide and sulfate conjugates , reaching peak concentrations in the former around 30-min after consumption . The free polyphenols accounted for 1.7 to 1.9 % ( trans-resveratrol ) , 1.1 to 6.5 % ( [+]-catechin ) and 17.2 to 26.9 % ( quercetin ) of the peak serum concentrations . The absorption of trans-resveratrol was the most efficient as judged by peak serum concentration , area-under-the curve ( 4 h ) and urinary 24-h excretion ( 16 - 17 % of dose consumed ) . [+]-Catechin was the poorest by these criteria ( urine 24-h excretion 1.2%-3.0 % of dose consumed ) , with quercetin being intermediate ( urine 24-h excretion 2.9%-7.0 % of dose consumed ) . Some significant matrix effects were observed for the serum polyphenol concentrations , but in the case of urine no matrix promoted significantly higher excretion than the other two . CONCLUSIONS The absorption of these three polyphenols is broadly equivalent in aqueous and alcoholic matrices but , at peak concentrations of 10 to 40 nmol/L , is inadequate to permit circulating concentrations of 5 to 100 micromol/L consistent with in vitro biologic activity . The voluminous literature reporting powerful in vitro anticancer and antiinflammatory effects of the free polyphenols is irrelevant , given that they are absorbed as conjugates OBJECTIVE Smokers are characterized by a low- grade systemic inflammatory state and an oxidant-antioxidant imbalance . Few human studies were conducted on the effects of resveratrol , a natural compound with anti-inflammatory and antioxidant properties , and no trial on smokers has been performed to date . We evaluated whether resveratrol has beneficial effects on markers of inflammation and oxidative stress in smokers . METHODS AND RESULTS A r and omized , double- blind , cross-over trial was performed in 50 healthy adult smokers : 25 were r and omly allocated to " resveratrol-first " ( 30-days : 500 mg resveratrol/day , 30-days wash-out , 30-days placebo ) and 25 to " placebo-first " ( 30-days placebo , 30-days wash-out , 30-days 500 mg resveratrol/day ) . Resveratrol significantly reduced C-reactive protein ( CRP ) and triglyceride concentrations , and increased Total Antioxidant Status ( TAS ) values . After analyzing data with general linear models to assess period and carry-over effects , the ratios of the values after resveratrol to those after placebo were respectively : 0.47 ( 95%CI 0.38 - 0.59 ) -CRP- and 0.71 ( 95%CI 0.65 - 0.78 ) -triglycerides- , while TAS increased by 74.2 μmol/L ( 95%CI 60.8 - 87.6 ) . Uric acid , glucose , insulin , cholesterol , liver enzyme concentrations , and weight , waist circumference , and blood pressure values did not significantly change after resveratrol supplementation . CONCLUSIONS Because resveratrol has anti-inflammatory , anti-oxidant , and hypotriglyceridemic effects , its supplementation may beneficially affect the increased cardiovascular risk of healthy smokers OBJECTIVE This study aim ed to evaluate the effects of short-term ( 60-d ) oral supplementation with calcium fructoborate , resveratrol , and their combination on the clinical and biological statuses of subjects with stable angina pectoris . METHODS A r and omized , double-blinded , active-controlled , parallel clinical trial was conducted in three groups of subjects . Of the total number of subjects included in study ( n = 166 ) , 87 completed the 60-d test treatment study period and 29 followed in parallel their usual medical care and treatment . The primary outcomes were inflammation biomarkers ( high-sensitivity C-reactive protein ) , left ventricular function markers ( N-terminal prohormone of brain natriuretic peptide ) , and lipid markers ( total cholesterol , low-density lipoprotein cholesterol , high-density lipoprotein cholesterol , and triacylglycerols ) . Quality of life was assessed by the Canadian Cardiovascular Society angina class and the number of angina attacks per week . RESULTS There was a significant decrease of high-sensitivity C-reactive protein in all groups at the 30-d and 60-d visits . This decrease was greater ( 39.7 % at 60 d ) for group 3 ( calcium fructoborate ) , followed by group 2 ( resveratrol plus calcium fructoborate , 30.3 % at 60 d ) . The N-terminal prohormone of brain natriuretic peptide was significantly lowered by resveratrol ( group 1 , 59.7 % at 60 d ) and by calcium fructoborate ( group 3 , 52.6 % at 60 d ) . However , their combination ( group 2 ) was the most effective and induced a decrease of 65.5 % . Lipid markers showed slight changes from baseline in all groups . The improvement in the quality of life was best observed for subjects who received the resveratrol and calcium fructoborate mixture ( group 2 ) . CONCLUSION The results indicate that the combination of resveratrol and calcium fructoborate has beneficial effects in patients with The search for complementary treatments in primary prevention of cardiovascular disease ( CVD ) is a high-priority challenge . Grape and wine polyphenol resveratrol confers CV benefits , in part by exerting anti-inflammatory effects . However , the evidence in human long-term clinical trials has yet to be established . We aim ed to investigate the effects of a dietary resveratrol-rich grape supplement on the inflammatory and fibrinolytic status of subjects at high risk of CVD and treated according to current guidelines for primary prevention of CVD . Seventy-five patients undergoing primary prevention of CVD participated in this triple-blinded , r and omized , parallel , dose-response , placebo-controlled , 1-year follow-up trial . Patients , allocated in 3 groups , consumed placebo ( maltodextrin ) , a resveratrol-rich grape supplement ( resveratrol 8 mg ) , or a conventional grape supplement lacking resveratrol , for the first 6 months and a double dose for the next 6 months . In contrast to placebo and conventional grape supplement , the resveratrol-rich grape supplement  significantly decreased high-sensitivity C-reactive protein ( -26 % , p = 0.03 ) , tumor necrosis factor-α ( -19.8 % , p = 0.01 ) , plasminogen activator inhibitor type 1 ( -16.8 % , p = 0.03 ) , and interleukin-6/interleukin-10 ratio ( -24 % , p = 0.04 ) and increased anti-inflammatory interleukin-10 ( 19.8 % , p = 0.00 ) . Adiponectin ( 6.5 % , p = 0.07 ) and soluble intercellular adhesion molecule-1 ( -5.7 % , p = 0.06 ) tended to increase and decrease , respectively . No adverse effects were observed in any patient . In conclusion , 1-year consumption of a resveratrol-rich grape supplement  improved the inflammatory and fibrinolytic status in patients who were on statins for primary prevention of CVD and at high CVD risk ( i.e. , with diabetes or hypercholesterolemia plus ≥1 other CV risk factor ) . Our results show for the first time that a dietary intervention with grape resveratrol could complement the gold st and ard therapy in the primary prevention of CVD Non-alcoholic fatty liver disease ( NAFLD ) is usually associated with insulin resistance , central obesity , reduced glucose tolerance , type 2 diabetes mellitus and hypertriacylglycerolaemia . The beneficial effects of resveratrol on metabolic disorders have been shown previously . The aim of this study was to evaluate the effects of resveratrol supplementation on cardiovascular risk factors in patients with NAFLD . In this r and omised double-blinded placebo-controlled clinical trial , fifty NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks . Both groups were advised to follow an energy-balanced diet and physical activity recommendations . resveratrol supplementation reduced alanine aminotransferase ( ALT ) and hepatic steatosis significantly more than placebo ( P0·05 ) . There were no significant changes in blood pressure , insulin resistance markers and TAG in either group ( P>0·05 ) . Our data have shown that 12-week supplementation of 500 mg resveratrol does not have any beneficial effect on anthropometric measurements , insulin resistance markers , lipid profile and blood pressure ; however , it reduced ALT and hepatic steatosis in patients with NAFLD Abstract High cholesterol is one of the risk factors for atherogenesis , leading to oxidative stress and cardiovascular disease ( CVD ) . The focus of this study was to evaluate the role and the pathways of action of a natural antioxidant , resveratrol , in asymptomatic hypercholesterolemic ( AHC ) individuals . Forty healthy AHCs and normocholesterolemics ( NCs ) participated in the study . They received r and om-order resveratrol and placebo capsules for four weeks . Total antioxidant capacity ( TAC ) , vitamin E and total cholesterol ( TC ) were measured at baseline and at the end of each intervention . Resveratrol provided a direct antioxidant effect in healthy NC individuals , but in AHC individuals , with a higher dem and for antioxidant activity due to higher cholesterol levels , it acted by facilitating an increase in vitamin E. Our findings suggest that resveratrol acts synergistically with other antioxidants against oxidative stress and highlights the importance of hypercholesterolemic individuals consuming natural antioxidants instead of medications to reduce the risk of CVD , while the situation is still reversible Probiotic therapies are going to be an effective alternative therapeutic strategy in the treatment and management of diabetes . The mechanism behind the essential effects of probiotic therapies in diabetic patients was not fully understood . The objective of this study was to evaluate the effects of probiotic soy milk containing Lactobacillus planetarum A7 on inflammation , lipid profile , fasting blood glucose , and serum adiponectin among patients with type 2 diabetes mellitus . Forty patients with type 2 diabetes , at the age of 35–68 years old , were assigned to two groups in this r and omized , double-blind , controlled clinical trial . The patients in the intervention group consumed 200 ml/day of probiotic soy milk containing L. planetarum A7 and those in control group consumed 200 ml/day of pure soy milk for 8 weeks  . Serum TNF-α , C reactive protein , adiponectin , lipid profile , and fasting blood glucose were determined before and after intervention . In intervention group , serum adiponectin in pre- and post-treatment did not show any significant changes ( 2.52 ± 0.74 vs 2.84 ± 0.61 , P = 0.658 ) , as well as changes in serum TNF-α and C reactive protein ( 172.44 ± 5.7 vs 172.83 ± 7.6 , P = 0.278 , 4.2 ± 1.4 vs 4.5 ± 1.9 , P = 0.765 , respectively ) . Low-density cholesterol and high-density cholesterol changed significantly ( P = 0.023 , P = 0.017 , respectively ) , but fasting blood glucose did not show any significant changes . The results of this study showed that consumption of probiotic soy milk and soy milk has no effect on serum adiponectin and inflammation , but it can change lipid profile among type 2 diabetic patients The aim of this study was to investigate the impact of resveratrol supplementation along with non-surgical periodontal treatment on blood glucose , insulin , insulin resistance , triglyceride ( TG ) , and periodontal markers in patients with type 2 diabetes with periodontal disease . In this double-blind clinical trial study , 43 patients with diabetes with chronic periodontitis were participated . Subjects were r and omly allocated to intervention and control groups . The intervention and control groups received either 480 mg/day of resveratrol or placebo capsules ( two pills ) for 4 weeks . Fasting blood glucose , insulin , insulin resistance ( homeostasis model assessment of insulin resistance ) , TGs , and pocket depth were measured in all subjects ' pre-intervention and post-intervention . The mean serum levels of fasting insulin and insulin resistance ( homeostasis model assessment of insulin resistance ) were significantly lower in the intervention group compared with control group ( 10.42 ± 0.28 and 10.92 ± 0.9 ; 3.66 ± 0.97 and 4.49 ± 1.56 , respectively ) . There was a significant difference in the mean pocket depth between intervention and control groups ( 2.35 ± 0.6 and 3.38 ± 0.5 , respectively ) following intervention . No significant differences were observed in the mean levels of fasting blood glucose and TGs between two groups ' post-intervention . It is recommended that resveratrol supplementation may be beneficial as adjuvant therapy along with non-surgical periodontal treatment in insulin resistance and improving periodontal status among patients with diabetes with periodontal disease . Copyright © 2016 John Wiley & Sons , BACKGROUND Sirtuin 1 ( Sirt1 ) plays an important role in vascular biology , and influences aspects of age-dependent atherosclerosis . In animals , the sirtuin system is strongly influenced by resveratrol and caloric restriction , but its expression in humans is controversial . This study investigated the effects of resveratrol and caloric restriction on Sirt1 serum concentrations and vascular biomarkers in a healthy human population . METHODS AND RESULTS Forty-eight healthy participants ( 24 women ) aged 55 - 65years were r and omized to either 30days of resveratrol administration ( 500mg/day ) or caloric restriction ( 1000cal/day ) . Blood was collected at baseline and day 30 . Laboratory data analyzed were triglycerides , total cholesterol , HDL , VLDL , LDL , apolipoprotein A1 , apolipoprotein B , lipoprotein ( a ) , non-esterified fatty acids ( NEFA ) , glucose , insulin , oxidative stress , C-reactive protein , and Sirt1 . Expression of the Sirt1 gene was analyzed using real-time PCR . Caloric restriction diminished the abdominal circumference and improved the lipid profile , but not resveratrol intervention . Resveratrol and caloric restriction increased serum concentrations of Sirt1 , from 1.06±0.71 to 5.75±2.98ng/mL ; p<0.0001 , and from 1.65±1.81 to 5.80±2.23ng/mL ; p<0.0001 , respectively . Sirt1 increased in women and men in both interventions . On the other h and expression of Sirt1 mRNA was not different after caloric restriction and resveratrol treatment . CONCLUSIONS Caloric restriction and resveratrol significantly increased plasma concentrations of Sirt1 . The long-term impact of these interventions on atherosclerosis should be assessed SCOPE The cardioprotective role of resveratrol as part of the human diet is not yet clear . Our aim was to investigate the effect of a grape supplement containing 8 mg resveratrol in oxidized LDL ( LDLox ) , apolipoprotein-B ( ApoB ) , and serum lipids on statin-treated patients in primary cardiovascular disease prevention ( PCP ) . METHODS AND RESULTS A triple-blind , r and omized , placebo-controlled trial was conducted . Seventy-five patients ( three parallel arms ) consumed one capsule ( 350 mg ) daily for 6 months containing resveratrol-enriched grape extract ( GE-RES , Stilvid ® ) , grape extract ( GE , similar polyphenolic content but no resveratrol ) , or placebo ( maltodextrin ) . After 6 months , no changes were observed in the placebo group and only LDL cholesterol ( LDLc ) decreased by 2.9 % ( p = 0.013 ) in the GE group . In contrast , LDLc ( -4.5 % , p = 0.04 ) , ApoB ( -9.8 % , p = 0.014 ) , LDLox ( -20 % , p = 0.001 ) , and LDLox/ApoB ( -12.5 % , p = 0.000 ) decreased in the Stilvid ® group , whereas the ratio non-HDLc ( total atherogenic cholesterol load)/ApoB increased ( 8.5 % , p = 0.046 ) . No changes were observed in hepatic , thyroid , and renal function . No adverse effects were observed in any of the patients . CONCLUSION This GE-RES reduced atherogenic markers and might exert additional cardioprotection beyond the gold-st and ard medication in patients from PCP . The presence of resveratrol in the GE was necessary to achieve these effects PURPOSE The purpose of this study was to determine the plasma metabolic response and certain indicators of oxidative stress ( antioxidant system and oxidative stress biomarkers ) in plasma and erythrocytes of Brazilian military firefighters supplemented or not with resveratrol ( RES ) for 90 days ( 100 mg/day ) . The analyses were performed before and after a typical physical fitness test ( FT ) used to induce oxidative stress . METHODS / RESULTS In this placebo-controlled double-blinded study , we observed that RES supplementation did not present hepatic consequences compared with the placebo group following analysis of AST , ALT and GGT plasma activities . Plasma glucose and triglycerides levels were increased after the FT in firefighters supplemented with RES but were not elevated at baseline . Neither total nor cholesterol fractions were modified by RES supplementation . CK levels were increased after the firefighters performed the FT ; however , no differences were determined between the placebo and RES groups . Ferric-reducing ability of plasma as well as uric acid was increased after the FT , but was not modified by RES supplementation . Plasma oxidative stress biomarkers , such as thiol content , 8-isoprostane and 8OHdG , showed no modifications , while IL-6 and TNF-α were decreased in the RES group after the FT . Among antioxidant enzyme activities determined in erythrocytes from the firefighters , only GPx activity was reduced by RES supplementation both before and after the FT . CONCLUSION In summary , the most pronounced effect of RES supplementation is its anti-inflammatory effect , which reduced IL-6 and TNF-α level . The FT applied to Brazilian military firefighters was not sufficient to challenge the antioxidant defense systems , and , therefore , 100 mg of RES for three months did not induce significant effects
target: We conclude that resveratrol does not change lipid profile concentration .
background: A : Meta‐ analysis of the effect of resveratrol supplementation on total cholesterol .
  B : Meta‐ analysis of the effect of resveratrol supplementation on low‐density lipoprotein .
  C : Meta‐ analysis of the effect of resveratrol supplementation on high‐density lipoprotein .
  D : Meta‐ analysis of the effect of resveratrol supplementation on triglyceride after removing the study by Zortea et al. & NA ; Despite the notion that resveratrol can significantly reduce plasma lipids , the result of r and omized clinical trials ( RCTs ) on resveratrol effect and the serum lipid profile are contradictory .
  Our objective was to conduct a systematic review and meta‐ analysis on r and omized clinical trials ( RCTs ) and assess the effect of resveratrol on lipids .